The A2M Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to abolish alpha-2-macroglobulin (A2M) expression in a human lung adenocarcinoma background. Created by CRISPR/Cas9-mediated gene disruption, this loss-of-function model enables systematic analysis of A2M-dependent processes without clonal selection, preserving cellular heterogeneity for experiments requiring a diverse gene-edited pool.
The A-549 cell line, derived from a 58-year-old male with lung adenocarcinoma, is an adherent epithelial line that serves as a model for type II alveolar epithelium. These cells are widely employed in respiratory disease and cancer research, facilitating studies on chronic obstructive pulmonary disease (COPD), emphysema, and lung adenocarcinoma biology. Their robust phenotypic characteristics and ease of culture make them a standard platform for investigating alveolar epithelial cell function, drug responses, and molecular pathology.
A2M encodes alpha-2-macroglobulin, a homotetrameric glycoprotein that irreversibly inhibits proteases such as trypsin, thrombin, and plasmin by a unique trapping mechanism. Beyond protease inhibition, A2M binds cytokines??most notably TGF-??1 and TGF-??2??as well as IL-1?? and TNF-??, controlling their extracellular bioavailability. A2M expression is induced by inflammatory stimuli, including IL-6, IL-1??, and TNF-??, through the transcription factors NF-??B and STAT3. By sequestering TGF-??, A2M dampens SMAD2/3 signaling and intersects with complement and coagulation cascades and LRP1-mediated endocytosis. Additional interactions with PDGF, NGF-??, and amyloid-beta peptide position A2M at the crossroads of immune regulation, tissue remodeling, and neurodegeneration.
In the A-549 lung adenocarcinoma context, A2M deficiency disrupts the proteolytic and cytokine equilibrium, potentially elevating free protease levels and TGF-?? bioactivity. This imbalance can promote epithelial-mesenchymal transition, extracellular matrix degradation, and acquisition of invasive traits, while simultaneously altering paracrine signaling to stromal and immune cells. The polyclonal knockout population thus provides a powerful tool to dissect A2M-mediated control of SMAD-dependent transcription, non-canonical TGF-?? pathways, and cross-regulation with MAPK and NF-??B cascades that drive tumor progression and inflammation in the lung.
These polyclonal knockout cells are ideally suited for a wide array of functional assays. Researchers can quantify protease activity using fluorogenic substrates, measure TGF-?? signaling with SMAD-responsive luciferase reporters, and assess metastatic potential via migration and invasion assays. Biochemical approaches such as co-immunoprecipitation and ELISA enable detection of A2M-protease complexes and secreted A2M, while RT-qPCR and western blotting confirm gene and protein expression changes. Transcriptomic profiling by RNA-seq can uncover genome-wide effects of A2M loss on matrix metalloproteinases, inflammatory mediators, and downstream SMAD targets. This product supports advanced investigations into protease inhibition and cytokine regulation in lung adenocarcinoma, COPD, and related inflammatory diseases. For further information or inquiries about custom gene-editing services, please contact Ascent Research.
